The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
Abstract
To determine whether the risk of adverse cardiovascular (CV) outcomes associated with diabetes differs in patients with low and preserved ejection fraction (EF) heart failure (HF). We analysed outcomes in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme which randomized 7599 patients with symptomatic HF and a broad range of EF. The prevalence of diabetes was 28.3% in patients with preserved EF (>40%) and 28.5% in those with low EF (≤40%). Diabetes was associated with a greater relative risk of CV death or HF hospitalization in patients with preserved EF [hazard ratio (HR) 2.0 (1.70–2.36)] than in patients with low EF [HR 1.60 (1.44–1.77); interaction test P = 0.0009]. For all-cause mortality, the risk conferred by diabetes was similar in both low and preserved EF groups. The effect of candesartan in reducing CV morbidity and mortality outcomes was not modified by having diabetes at baseline (P = 0.09 test for interaction). Diabetes was an independent predictor of CV morbidity and mortality in patients with HF, regardless of EF. The relative risk of CV death or HF hospitalization conferred by diabetes was significantly greater in patients with preserved when compared with those with low EF HF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [477]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients) and associated with a higher risk of HF hospitalization, all-cause and cardiovascular (CV) mortality.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [1]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients) and associated with a higher risk of HF hospitalization, all-cause and cardiovascular (CV) mortality.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [1]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients) and associated with a higher risk of HF hospitalization, all-cause and cardiovascular (CV) mortality.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [1]
In the citing paper
“T2DM is associated with worse clinical status and increased all-cause and cardiovascular (CV) mortality in both patients with HF with reduced (HFrEF) and preserved ejection fraction (HFpEF), compared to HF patients without T2DM. 1”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [1]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., Carson, P., DiCarlo, L., DeMets, D., White, B. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032423 · Cited by 5,812
Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,889
Self-citationSurvival after the onset of congestive heart failure in Framingham Heart Study subjects.
Ho, K. K., Anderson, K. M., Kannel, W. B., Grossman, W., & Levy, D. (1993) · Circulation · doi:10.1161/01.cir.88.1.107 · Cited by 1,869
The perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Heart failure with preserved left ventricular systolic function
Hogg, K., Swedberg, K., & McMurray, J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.046 · Cited by 932
Self-citationOlsson, L. G., Swedberg, K., Ducharme, A., Granger, C. B., Michelson, E. L., McMurray, J. J. V., Puu, M., Yusuf, S., & Pfeffer, M. A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.060 · Cited by 574
Self-citationDiabetic Cardiomyopathy: The Search for a Unifying Hypothesis
Poornima, I. G., Parikh, P., & Shannon, R. P. (2006) · Circulation Research · doi:10.1161/01.res.0000207406.94146.c2 · Cited by 571
Shindler, D. M., Kostis, J. B., Yusuf, S., Quinones, M. A., Pitt, B., Stewart, D., Pinkett, T., Ghali, J. K., Wilson, A. C., & The SOLVD Investigators (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89163-1 · Cited by 516
Self-citationThrainsdottir, I. S., Aspelund, T., Thorgeirsson, G., Gudnason, V., Hardarson, T., Malmberg, K., Sigurdsson, G., & Rydén, L. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.612 · Cited by 374
Swedberg, K., Pfeffer, M., Granger, C., Held, P., Mcmurray, J., Ohlin, G., Olofsson, B., Östergren, J., & Yusuf, S. (1999) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(99)90013-1 · Cited by 294
Self-citation
Cited by
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
“DM and ischaemic heart disease may interact to accelerate the deterioration of myocardial dysfunction, HF progression, and unfavourably influence prognosis.(179,180) † Although the relationship between elevated glucose level and a higher risk for HF is established in patients with DM, a direct beneficial effect of glu…”
Self-citationGlobal burden of heart failure: a comprehensive and updated review of epidemiology
Savarese, G., Becher, P. M., Lund, L. H., Seferovic, P., Rosano, G. M. C., & Coats, A. J. S. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac013 · Cited by 3,315
Authors/Task Force Members, Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn309 · Cited by 2,696
Self-citation(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Metadata
- Authors
- MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., Pfeffer, M. A., McMurray, J. J. V., & and for the CHARM Investigators
- Affiliations
- Glasgow Royal Infirmary (GB)
- University of Glasgow (GB)
- AstraZeneca (United States) (US)
- Cleveland Clinic (US)
- Brigham and Women's Hospital (US)
- Duke University (US)
- University of Gothenburg (SE)
- Population Health Research Institute (CA)
- Corresponding author
- McMurray, J. J.V.
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01-18
- Volume
- 29
- Issue
- 11
- Pages
- 1377-1385
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W1821804635
- Cited by
- 694
- References
- 21
- Citations by year
- 2026: 15 · 2025: 42 · 2024: 61 · 2023: 52 · 2022: 49 · 2021: 86 · 2020: 74 · 2019: 68 · 2018: 41 · 2017: 54 · 2016: 31 · 2015: 22 · 2014: 21 · 2013: 10 · 2012: 13
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- diabetes mellitus, heart failure, ejection fraction, preserved ejection fraction, reduced ejection fraction, candesartan, cardiovascular mortality, heart failure hospitalization, all-cause mortality, cardiovascular morbidity, CHARM trial, ACE inhibitors
- MeSH terms
- Aged, Benzimidazoles, Biphenyl Compounds, Diabetic Angiopathies, Epidemiologic Methods, Female, Heart Failure, Humans, Male, Prognosis, Stroke Volume, Tetrazoles, Treatment Outcome, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. https://app.cochat.ai/papers/10.1093/eurheartj/ehn153
- The paper
- MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., Pfeffer, M. A., McMurray, J. J. V., & and for the CHARM Investigators. (2008). Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal. https://doi.org/10.1093/eurheartj/ehn153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.